Additional clinical validation of the activity of DLinMC3DMA was observed in a Phase 1 clinical trial of ALN-PCS02, containing an siRNA directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of severe hypercholesterolemia. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.